血必净治疗脓毒性休克疗效探讨  

Therapeutic Effect of Xuebijing on Septic Shock

作　　者：罗雪莲 LUO Xue-lian(Department of Critical Care Medicine, the People's Hospital of Xingbin District, Laibin, Guangxi, 546100 China)

机构地区：[1]广西来宾市兴宾区人民医院重症医学科,广西来宾546100

出　　处：《中外医疗》2019年第3期108-110,117,共4页China & Foreign Medical Treatment

摘　　要：目的分析血必净治疗脓毒性休克的疗效。方法按照随机数字表法将方便选取的该院在2017年6月—2018年6月收治的60例脓毒性休克患者分为治疗组(30例)与对照组(30例),对照组采取常规治疗,治疗组在对照组的基础上加用血必净治疗,就两组患者的死亡率、病情严重程度、血流动力学、血清细胞因子、心损伤标志物进行分析和比较。结果两组患者死亡率差异无统计学意义(10.0%vs 16.7%),组间对比差异无统计学意义(χ2=0.577,P=0.448);治疗组患者APACHEⅡ评分[(12.7±4.0)分vs(16.0±4.5)分](t=3.002,P=0.004)、hs-CRP[(53.4±6.6)mg/L vs(69.2±8.0)mg/L](t=8.344,P=0.000)、BNP[(519.4±136.7)pg/mL vs (638.4±150.6)pg/mL](t=3.205,P=0.002)、c Tnl[(1.0±0.3)μg/L vs(1.7±0.5)μg/L](t=6.575,P=0.000)、CK-MB[(96.8±33.1)IU/L vs(151.0±40.9)IU/L](t=3.560,P=0.001)均显著低于对照组,DBP[(63.3±5.2)mmHg vs (53.8±4.9)mmHg](t=7.283,P=0.000)、SBP[(97.0±9.8)mmHg vs (82.4±9.0)mmHg](t=6.010,P=0.000)、MAP[(79.5±8.4)mmHg vs (68.4±7.8)mmHg](t=5.304,P=0.000)、CVP[(7.2±1.9)mmHg vs (5.6±1.6)mmHg](t=6.528,P=0.001)均显著高于对照组。结论对脓毒性休克患者给予血必净治疗可取得较好的临床疗效,可有效改善其血流动力学和心功能,降低血清细胞因子水平,建议将这一治疗方案在临床中推广应用。Objective To analyze the efficacy of Xuebijing in the treatment of septic shock. Methods According to the random number table method, 60 patients with septic shock admitted to our hospital from June 2017 to June 2018 were convenient selected and divided into treatment group (30 cases) and control group (30 cases). The control group received routine treatment. The treatment group was treated with Xuebijing on the basis of the control group, and the mortality, severity, hemodynamics, serum cytokines and heart injury markers of the two groups were analyzed and compared. Results There was no significant difference in mortality between the two groups (10.0% vs 16.7%). There was no statistically significant difference between the two groups (χ^2=0.577, P=0.448). The APACHEII score of the patients in the treatment group[(12.7±4.0)points vs (16.0±4.5)points](t=3.002, P=0.004), hs-CRP [(53.4±6.6) mg/L vs (69.2±8.0) mg/L](t=8.344, P=0.000), BNP[(519.4±136.7) pg/mL vs (638.4±150.6)pg/mL](t=3.205, P=0.002), cTnl [(1.0±0.3)μg/L vs (1.7±0.5)μg/L](t=6.575, P= 0.000), CK-MB [(96.8±33.1)IU/L vs (151.0±40.9) IU/L](t=3.560, P= 0.001) were significantly lower than the control group, DBP [(63.3±5.2)mmHg vs (53.8±4.9)]mmHg (t=7.283, P=0.000), SBP[(97.0±9.8)mmHg vs (82.4±9.0)]mmHg (t=6.010, P=0.000), MAP[(79.5±8.4)mmHg vs (68.4±7.8)mmHg](t=5.304, P=0.000), CVP [(7.2±1.9)mmHg vs (5.6±1.6)mmHg](t=6.528, P=0.001) were significantly higher than the control group. Conclusion The treatment of Xuebijing in patients with septic shock can achieve better clinical efficacy, improve hemodynamics and cardiac function, and reduce serum cytokine levels. It is recommended to promote this treatment in clinical practice.

关 键 词：脓毒性休克 血必净 血流动力学 血清细胞因子 心损伤标志物 

分 类 号：R5[医药卫生—内科学]